FDA Approves First Symptomatic Dermographism Treatment
FDA approves Novartis Rhapsido (remibrutinib) as the first treatment for symptomatic dermographism. RemIND Phase III data, safety and what patients should know.
FDA approves Novartis Rhapsido (remibrutinib) as the first treatment for symptomatic dermographism. RemIND Phase III data, safety and what patients should know.